Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases

American Journal of Respiratory Cell and Molecular Biology

Volumn 20, Issue 5, 1999, Pages 935-941

  Hirschowitz, Edward A ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRIDAE; MURINAE;

INTERLEUKIN 12; TUMOR ANTIGEN;

ADENOVIRUS; ADOPTIVE TRANSFER; ANIMAL; ARTICLE; EXPERIMENTAL MELANOMA; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METASTASIS; MOUSE; NATURAL KILLER CELL; PATHOLOGY;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; GENETIC VECTORS; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE;

EID: 0033128827     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.20.5.3412     Document Type: Article

References (66)

1. Zitvogel, L., and M. T. Lotze. 1995. Role of interleukin-12 (IL-12) as an anti-tumor agent: experimental biology and clinical application. Res. Immunol. 146:628-638.
2. Brunda, M. J., L. Luistro, L. Rumennik, R. B. Wright, M. Dvorozniak, A. Aglione, J. M. Wigginton, R. H. Wiltrout, J. A. Hendrzak, and A. V. Palleroni. 1996. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol 38(Suppl.)S16-S21.
3. Klein, E., and A. Mantovani. 1993. Action of natural killer cells and macrophages in cancer. Curr. Opin. Immunol. 5:714-718.
4. D'Andrea, A., C. Chang, J. J. Phillips, and L. L. Lanier. 1996. Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self HLA class I alleles. J. Exp. Med. 184:789-794.
5. Gately, M. K., R. R. Warrier, S. Honasoge, D. M. Carvajal, D. A. Faherty, S. E. Connaughton, T. D. Anderson, U. Sarmiento, B. R. Hubbard, and M. Murphy. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol. 6:157-167.
6. Manetti, R., F. Gerosa, M. G. Giudizi, R. Biagiotti, P. Parronchi, M. P. Piccinni, S. Sampognaro, E. Maggi, S. Romagnani, and G. Trinchieri. 1994. Interleukin 12 induces stable priming for interferon γ (IFN-γ) production during differentiation of human T helper (Th) cells and transient IFN-γ production is established Th2 cell clones. J. Exp. Med. 179:1273-1283.
7. O'Garra, A., N. Hosken, S. Macatonia, C. A. Wenner, and K. Murphy. 1995. The role of macrophage- and dendritic cell-derived IL-12 in Th1 phenotype development. Res. Immunol. 146:466-472.
8. Trinchieri, G., and P. Scott. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res. Immunol. 146:423-431.
9. Fujiwara, H., J. P. Zou, S. Herrmann, and T. Hamaoka. 1995. A sequence of cellular and molecular events involved in IL12-induccd tumor regression. Res. Immunol. 146:638-644.
10. Garbe, C., and K. Krasagakis. 1993. Effects of interferons and cytokines on melanoma cells. J. Invest. Dermatol. 100:239S-244S.
11. Taniguchi, K., M. Petersson, P. Hoglund, R. Kiessling, G. Klein, and K. Karre. 1987. Interferon γ induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. USA 84: 3405-3409.
12. Hirschowitz, E. A., S. Leonard, W. Song, B. Ferris, P. L. Leopold, J. Lewis, W. B. Bowne, S. Wang, A. N. Houghton, and R. G. Crystal. 1998. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther.
13. Bramson, J., M. Hitt, W. S. Gallichan, K. L. Rosenthal, J. Gauldie, and F. L. Graham. 1996. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum. Gene Ther. 7:333-342.
14. Hersh, J., R. G. Crystal, and B. Bewig. 1995. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther. 2:124-131.
15. Hirschowitz, E. A., A. Ohwada, W. R. Pascal, T. J. Russi, and R. G. Crystal. 1995. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther. 6:1055-1063.
16. Rosenfeld, M. A., K. Yoshimura, B. C. Trapnell, K. Yoneyama, E. R. Rosenthal, W. Dalemans, M. Fukayama, J. Bargon, L. E. Stier, L. D. Stratford-Perricaudet, M. Perricaudt, W. B. Guggino, A. Pavirani, J. P. Lecocq, and R. G. Crystal. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155.
17. Hara, I., Y. Takechi, and A. N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein. J. Exp. Med. 182:1609-1614.
18. De Giovanni, C., P. L. Lollini, G. Nicolelti, B. Del Re, K. Scotlandi, G. Prodi, and P. Naoni. 1987. Growth and metastasis in allogeneic hosts: lack of H-2-negative or somatic hybrid variant selection. Exp. Clin. Immuno-genet. 4:153-162.
19. Zoller, M. 1988. IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread. Clin. Exp. Metastasis 6:411-429.
20. Kameyama, K., W. D. Vieira, K. Tsukamoto, L. W. Law, and V. J. Hearing. 1990. Differentiation and the tumorigenetic and metastatic phenotype of murine melanoma cells. Int. J. Cancer 45:1151-1158.
21. Holseher, M., A. L. Givan, and C. G. Brooks. 1991. The effect of tramfected MHC class I genes on sensitivity to natural killer cells. Immunology 73:44-51.
22. Poste, G., and I. J. Fidler. 1980. The pathogenesis of cancer metastasis. Nature 283:139-146.
23. Hanna, N., and R. C. Burton. 1981. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J. Immunol. 127: 1754-1758.
24. Decker, T., and M. L. Lohmann-Matthes. 1988 A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115:61-69.
25. Song, W., H. L. Kong, P. Traktman, and R. G. Crystal. 1997. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum. Gene Ther. 8:1207-1217.
26. Vijayasaradhi, S., B. Bouchard, and A. N. Houghton. 1990. The melanoma antigen gp75 is the human homologue of the mouse b (Brown) locus gene product. J. Exp. Med. 171:1375-1380.
27. Vijayasaradhi, S., P. M. Doskoch, and A. N. Houghton. 1991. Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (Brown) locus product. Exp. Cell Res. 196:233-240.
28. Vijayasaradhi, S., and A. N. Houghton. 1991. Purification of an autoantigenic 75-kDa human melanosomal glycoprotein. Int. J. Cancer 47:298-303.
29. Wang, R. F., P. F. Rohbins, Y. Kawakami, X. Q. Kang, and S. A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799-804.
30. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, and A. N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA 93:14809-14814.
31. Juillard, V., P. Villefroy, D. Godfrin, A. Pavirani, A. Venet, and J. G. Guillet. 1995. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 25:3467-3473.
32. Van Ginkel, F. W., C. Liu, J. W. Simecka, J. Y. Dong, T. Greenway, R. A. Frizzell, H. Kiyono, J. R. McGhee, and D. W. Pascual. 1995. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum. Gene Ther. 6:895-903.
33. Chen, P. W., M. Wang, V. Bronte, Y. Zhai, S. A. Rosenberg, and N. P. Restifo. 1996. Therapeutic antiturnor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156:224-231.
34. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
35. Yang, Y., K. U. Jooss, Q. Su, H. C. Ertl, and J. M. Wilson. 1996. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:137-144.
36. Zhai, Y., J. C. Yang, Y. Kawakami, P. Spiess, S. C. Wadsworth, L. M. Cardoza, L. A. Couture, A. E. Smith, and S. A. Rosenberg. 1996. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156:700-710.
37. Mack, C. A., W. R. Song, H. Carpenter, T. J. Wickman, I. Kovesdi, B. G. Harvey, C. J. Magovern, O. W. Isom, T. Rosengart, E. Falck-Pedersen, N. R. Hackett, R. G. Crystal, and A. Mastrangcli. 1997. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8:99-109.
38. Mortarini, R., F. Belli, G. Parmiani, and A. Anichini. 1990. Cytokine-mediated modulation of HLA-Class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-β, rTNF-α, rIFN-γ, rIL4 and their combinations. Int. J. Cancer 45:334-341.
39. Kalland, T. 1986. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 46:3018-3022.
40. Bramson, J. L., M. Hitt, C. L. Addison, W. J. Muller, J. Gauldie, and F. L. Graham. 1996. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7:1995-2002.
41. Caruso, M., K. Pham-Nguyen, Y. L. Kwong, B. Xu, K. I. Kosai, M. Fincgold, S. L. Woo, and S. H. Chen. 1996. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA 93:11302-11306.
42. Chen, L., D. Chen, E. Block, M. O'Donnell, D. W. Kufe, and S. K. Clinton. 1997. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J. Immunol. 159: 351-359.
43. Putzer, B. M., M. Hitt, W. J. Muller, P. Emtage, J. Gauldie, and F. L. Graham. 1997. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA 94:10889-10894.
44. Lee, Y. L. M. H. Tao, Y. H. Chow, and B. L. Chiang. 1998. Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy. Hum. Gene Ther. 9:457-465.
45. Gately, M. K., A. G. Wolitzky, P. M. Quinn, and R. Chizzonite. 1992. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol. 143:127-142.
46. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845.
47. Nishimura, T., K. Watanabe, T. Yahata, L. Ushaku, K. Ando, M. Kimura, I. Saiki, T. Uede, and S. Habu. 1996. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother. Pharmacol. 38(Suppl.): S27-S34.
48. Schmitt, M., H. Ikeda, Y. Nagata, X. Gu, L. Wang, K Kuribayashi, and H. Shiku. 1997. Involvement of T-cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes. Int. J. Cancer 72:505-511.
49. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178:1223-1230.
50. Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of interferon-γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:869-879.
51. Ma, X., A. D'Andrea, M. Kubin, M. Aste-Amezaga, A. Sartori, J. Monteiro, L. Showe, M. Wysocka, and G. Trinchieri. 1995. Production of interleukin-12. Res. Immunol. 146:432-438.
52. Colombo, M. P., M. Vagliani, F. Spreafico, M. Parenza, C. Chiodoni, C. Melani, and A. Stoppacciaro. 1996. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56:2531-2534.
53. Nastala, C. L., H. D. Ellington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant TL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697-1706.
54. Zitvogel, L., P. D. Robbins, W. J. Storkus, M. R. Clarke, M. J. Maeurer, R L. Campbell, C. G. Davis, H. Tahara, R. D. Schreiber, and M. T. Lotze. 1996. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26:1335-1341.
55. Cavallo, F., P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M. J. Brunda, M. P. Colombo, and G. Forni. 1997. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokincscompared with exogenous IL-12. J. Natl. Cancer Inst. 89:1049-1058.
56. Rao, J. B., R. S. Chamberlain, V. Bronte, M. W. Carroll, K. R. Irvine, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1996 IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156:3357-3365.
57. Coughlin, C. M., M. Wysocka, G. Trinchieri, and W. M. Lee. 1997. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res. 57:2460-2467.
58. Lamont, A. G., and L. Adorini. 1996. IL 12: a key cytokine in immune regulation. Immunol. Today 17:214-217.
59. Leonard, J. P., M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90:2541-2548.
60. Orange, J. S., T. P. Salazar-Mather, S. M. Opal, R. L. Spencer, A. H. Miller, B. S. McEwwn, and C. A. Biron. 1995. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 181:901-914.
61. Sacco, S., H. Heremans, B. Echtenacher, W. A. Buurman, Z. Amraoui, M. Goldman, and P. Ghezzi. 1997. Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids. Blood 90:4473-4479.
62. Meko, J. B., K. Tsung, and J. A. Norton. 1996. Cytokine production and antitumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12. Surgery 120:274-282; discussion 282-283.
63. Rodolfo, M., C. Zilocchi, C. Melani, B. Capetti, I. Arioli, G. Parmiani, and M. P. Colombo. 1996. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor -associated antigens. Comparison between IL-2 and IL-2 gene-transduced tumor cell vaccines. J. Immunol. 157:5536-5542.
64. Aruga, E., A. Aruga, M. J. Arca, W. M. Lee, N. S. Yang, J. W. Smith, II, and A. F., Chang. 1997. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Cancer Gene Ther. 4:157-166.
65. Rakhmilevich, A. L., J. Tuner, M. J. Ford, D. McCabe, W. H. Sun, P. M. Sondel, K. Grota, and N. S. Yang. 1996. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl. Acad. Sci. USA 93:6291-4296.
66. Tan, J., C. A. Newton, J. Y. Djeu, D. E. Gutsch, A. E. Chang, N. S. Yang, T. W. Klein, and Y. Hua. 1996. Injection of complementary DNA encoding interlcukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res. 56:3399-3403.